Current Report Filing (8-k)
September 24 2021 - 4:23PM
Edgar (US Regulatory)
0001174940
false
0001174940
2021-09-22
2021-09-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: September 22, 2021
(Date
of earliest event reported)
Oragenics,
Inc.
(Exact
name of registrant as specified in its charter)
FL
|
|
001-32188
|
|
59-3410522
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
Number)
|
4902
Eisenhower Boulevard, Suite 125
Tampa,
FL
|
|
33634
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
OGEN
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.02. Termination of a Material Definitive Agreement.
Oragenics,
Inc. (the “Company” or “we”) has a commitment to the continued research and development of lantibiotics for the
treatment of infectious diseases. In an effort to strengthen and streamline that commitment, on September 22, 2021, the Company and
Eleszto Genetika, Inc. mutually terminated the amended and restated worldwide exclusive channel collaboration agreement dated March 1,
2021 (the “Lantibiotic ECC”) pursuant to which the Company was pursuing the development of OG716 as a lead product candidate
for the treatment of C. diff.
As
a result of the mutual termination of the Lantibiotic ECC, the Company will cease pre-clinical development of its product candidate OG716
and other compounds covered by the Lantibiotic ECC, all licenses provided pursuant to the Lantibiotic ECC between the parties were terminated
and there are no continuing obligations between the parties, except as to confidentiality. The Company made no payments to EGI in connection
with the mutual termination. Each party retained all right and title to their own respective intellectual property.
The
Company will focus on its continuing independent research and development efforts relative to lantibiotics in order to identify new compounds
to pursue.
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on this 24th day of September, 2021.
|
ORAGENICS, INC.
(Registrant)
|
|
|
|
BY:
|
/s/
Michael Sullivan
|
|
|
Michael
Sullivan
|
|
|
Interim Principal Executive Officer
and
Chief Financial Officer
|
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024